Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCurrent AssetsCurrent Deferred RevenueCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNotes PayablesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zhengye Biotechnology Holding (ZYBT) Common Equity (2023 - 2024)

Historic Common Equity for Zhengye Biotechnology Holding (ZYBT) over the last 2 years, with Q4 2024 value amounting to $49.1 million.

  • Zhengye Biotechnology Holding's Common Equity rose 415.64% to $49.1 million in Q4 2024 from the same period last year, while for Dec 2024 it was $49.1 million, marking a year-over-year increase of 415.64%. This contributed to the annual value of $48.3 million for FY2024, which is 61.08% up from last year.
  • As of Q4 2024, Zhengye Biotechnology Holding's Common Equity stood at $49.1 million, which was up 415.64% from $47.1 million recorded in Q4 2023.
  • Zhengye Biotechnology Holding's Common Equity's 5-year high stood at $49.1 million during Q4 2024, with a 5-year trough of $47.1 million in Q4 2023.